We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Prescription medication — not a dietary supplement
Verapamilis a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
Most Verapamil studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from medium-quality meta-analyses and randomised trials published 2018–2026 with a typical study size of 88 participants.
Based on 7 studies · 1 meta-analysis · 3 RCTs · 112 total participants
Confidence
ModerateBy outcome
Verapamil has an evidence score of 4.6/10 — emerging evidence based on 7 indexed studies, including 1 meta-analysis. A decades-old non-dihydropyridine calcium-channel blocker for hypertension, angina, and arrhythmia, being repurposed to PRESERVE pancreatic beta-cell function in new-onset type-1 diabetes. Two randomized trials (adults — Nature Medicine 2018; children/adolescents — JAMA 2023, CLVer) show it partially preserves C-peptide. The benefit is partial and adjunctive — not a cure, and it wanes after stopping. A prescription drug, not a supplement. Representative study: PMID 40111679.
The commonly studied dose of Verapamil is Off-label beta-cell use in new-onset T1D mirrors trial dosing (the adult Ver-A-T1D trial used roughly weight-based ~120–360 mg/day of extended-release verapamil) added to a standard insulin regimen, under a clinician — ideally within a trial framework. A prescription drug; not an approved or standardized regimen for T1D.. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
Nicotinamide Riboside
Mostly mechanism / observationalA vitamin B3 precursor that reliably raises cellular NAD+ levels and is well tolerated — but human trials have so far shown mostly null or mixed results on the functional outcomes (muscle, metabolism, blood pressure, cognition) that elevation is meant to drive.
Alirocumab (Praluent)
Last reviewed June 2026 · evidence from 7 studies · how we score
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Verapamil (Calan / Isoptin) — non-dihydropyridine calcium-channel blocker
A decades-old non-dihydropyridine calcium-channel blocker for hypertension, angina, and arrhythmia, being repurposed to PRESERVE pancreatic beta-cell function in new-onset type-1 diabetes. Two randomized trials (adults — Nature Medicine 2018; children/adolescents — JAMA 2023, CLVer) show it partially preserves C-peptide. The benefit is partial and adjunctive — not a cure, and it wanes after stopping. A prescription drug, not a supplement.
Verapamil has two randomized, double-blind, placebo-controlled trials (adults — Nature Medicine 2018; children/adolescents — JAMA 2023) showing it partially preserves stimulated C-peptide in new-onset type-1 diabetes, grounded in a clear TXNIP/beta-cell mechanism and backed by decades of approved cardiovascular use — but the beta-cell benefit is partial, adjunctive, non-curative, appears to wane after stopping, and durability is unresolved, so the repurposing use stays emerging.
Verapamil is a non-dihydropyridine calcium-channel blocker approved for decades to treat hypertension, angina, and supraventricular arrhythmias by slowing AV-node conduction and relaxing vascular smooth muscle.
Its novel, evidence-backed repurposing is in type-1 diabetes: preclinical work showed that verapamil lowers expression of thioredoxin-interacting protein (TXNIP) in pancreatic beta cells — a protein that drives beta-cell apoptosis under glucotoxic stress — and that this promotes beta-cell survival.
That mechanism was translated to humans in two randomized, double-blind, placebo-controlled trials.
The Ver-A-T1D trial (Ovalle/Shalev, Nature Medicine 2018) found that once-daily oral verapamil added to insulin for 12 months in adults with recent-onset T1D improved mixed-meal-stimulated C-peptide (a measure of endogenous insulin/beta-cell function), reduced the rise in insulin requirements, and lowered hypoglycemic events.
The CLVer trial (Forlenza/Moran, JAMA 2023) replicated this in children and adolescents aged 7–17 with newly diagnosed T1D: verapamil partially preserved stimulated C-peptide at 52 weeks (about 30% higher than placebo).
The honest framing is that this is adjunctive, partial beta-cell preservation — verapamil does not cure T1D, does not eliminate insulin dependence, and the C-peptide benefit appears to wane after the drug is stopped; longer-term durability and optimal treatment length are unresolved.
As a cardiovascular drug verapamil is well characterized and generally well tolerated, but it carries real cardiac and GI trade-offs: bradycardia, AV block, hypotension, and constipation, plus contraindications in significant heart-failure or conduction disease.
Verapamil is a prescription drug used off-label for beta-cell preservation in T1D, ideally within or alongside a clinical-trial framework.
The score reflects genuinely randomized human evidence for a novel beta-cell-preserving effect plus decades of approved cardiovascular use, set against a benefit that is partial, adjunctive, non-curative, and not yet shown to be durable.
Verapamil decreases expression of thioredoxin-interacting protein (TXNIP), a driver of glucotoxicity-induced beta-cell apoptosis — promoting survival of insulin-producing beta cells.
Blocking L-type calcium channels lowers intracellular calcium overload (the upstream trigger for TXNIP induction) and underlies the approved cardiovascular effects on vascular tone and AV-node conduction.
Slowed AV-node conduction and vascular smooth-muscle relaxation deliver the established antiarrhythmic, antianginal, and antihypertensive actions — and the bradycardia/AV-block trade-off.
How Verapamil works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Tap node to isolate • Pinch to zoom • Tap edge for research
Off-label beta-cell use in new-onset T1D mirrors trial dosing (the adult Ver-A-T1D trial used roughly weight-based ~120–360 mg/day of extended-release verapamil) added to a standard insulin regimen, under a clinician — ideally within a trial framework. A prescription drug; not an approved or standardized regimen for T1D.
Loading: Titrate up gradually under monitoring (heart rate, blood pressure, AV conduction); no loading dose.
Take with food
| Form | Type |
|---|---|
| 💊Extended-release tablet | Recommended |
| 💊Immediate-release tablet | Alternative |
The beta-cell trials used oral verapamil added to insulin; this is an off-label use of a cheap generic cardiovascular drug.
Minimum: 12 weeks
Optimal: 52 weeks
Cycling: Not required
Note: Extended-release commonly once daily with food; titrate under monitoring of heart rate, blood pressure, and AV conduction.
Dose-response data unavailable. The current published research for Verapamil does not provide sufficient dose-specific outcome data to generate reliable dose-response curves.
Refer to the Dosage & Timing section above for recommended dose ranges based on available evidence.
Randomized trials in adults and in children/adolescents show partial preservation of stimulated C-peptide — the novel, repurposed effect. Adjunctive, not curative.
In the adult trial, verapamil slowed the rise in insulin requirements and reduced hypoglycemic events alongside on-target glycemic control.
Decades-established control of hypertension, angina, and supraventricular arrhythmias via vascular and AV-node effects.
The C-peptide benefit is partial, does not eliminate insulin dependence, and appears to wane once the drug is stopped — durability is unresolved.
Cardiac trade-offs include bradycardia, AV block, and hypotension; constipation is the most common non-cardiac side effect.
Beta-cell preservation is adjunctive to insulin, not a replacement — discuss with an endocrinologist, ideally within a trial framework.
Contraindicated or high-risk — verapamil depresses contractility and AV conduction.
High interaction risk — combined cardiac suppression or digoxin toxicity; close monitoring required.
Additive AV-node suppression — risk of severe bradycardia, heart block, and hypotension.
Verapamil raises digoxin levels — monitor for digoxin toxicity.
Tip: Most common side effect; maintain fluid/fiber intake; dose adjustment if persistent.
Tip: Monitor heart rate and blood pressure; caution with beta-blockers and in conduction disease.
Tip: Avoid in pre-existing high-grade AV block without a pacemaker; ECG monitoring during titration.
The best time to take Verapamil is with meals. Take it with food. Extended-release verapamil is taken with food, commonly once daily; titrate to limit bradycardia/hypotension and constipation.
Verapamil should be used with caution — talk to a healthcare provider before taking it. The most commonly reported side effects are constipation, bradycardia / hypotension / dizziness, AV block. Use caution if any of these apply to you: Significant left-ventricular dysfunction / decompensated heart failure; Severe bradycardia, sick-sinus syndrome, or second/third-degree AV block (without a pacemaker); Severe hypotension or cardiogenic shock.
A fully human monoclonal-antibody PCSK9 inhibitor (Praluent), injected under the skin every 2 weeks, that lowers LDL cholesterol by ~50–60%. In the ODYSSEY OUTCOMES trial of ~18,900 post-heart-attack patients it reduced major cardiovascular events and showed a possible all-cause mortality signal. Generally well tolerated; injection-site reactions and high cost/access are the main trade-offs. Prescription drug, not a supplement.
Verapamil inhibits CYP3A4, raising levels of some statins (myopathy risk) and other substrates; avoid grapefruit juice.